1 week Ago By ABMN Staff
uniQure ( NASDAQ:QURE – Get Free Report ) has received an average rating of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $18.
60. A number of research analysts have recently commented on QURE shares. StockNews.
com raised shares of uniQure to a “sell” rating in a research report on Monday, August 5th. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 target price on shares of uniQure in a research note on Tuesday, July 16th.
HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a report on Tuesday, August 20th. Finally, The Goldman Sachs Group lifted their price objective on uniQure from $6.
00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Check Out Our Latest Research Report on QURE Hedge Funds Weigh In On uniQure uniQure Price Performance Shares of NASDAQ:QURE opened at $5.
42 on Friday. The business has a fifty day simple moving average of $6.83 and a 200-day simple moving average of $5.
67. The company has a quick ratio of 7.36, a current ratio of 7.
36 and a debt-to-equity ratio of 1.06. uniQure has a 52 week low of $3.
73 and a 52 week high of $11.35. The company has a market cap of $263.
14 million, a P/E ratio of -0.87 and a beta of 0.95.
uniQure ( NASDAQ:QURE – Get Free Report ) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.
24) by $0.08. The company had revenue of $11.
13 million during the quarter, compared to analyst estimates of $3.47 million. uniQure had a negative return on equity of 158.
09% and a negative net margin of 1,027.52%. Equities research analysts forecast that uniQure will post -4.
04 EPS for the current year. About uniQure ( Get Free Report uniQure N.V.
develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Read More Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter ..
